AR-13324 Ophthalmic Solution 0.02%

DRUG7 trials

Sponsors

Aerie Pharmaceuticals

Conditions

GlaucomaOcular HypertensionOpen Angle GlaucomaOpen-angle GlaucomaPrimary Open Angle Glaucoma or Ocular Hypertension

Phase 2

Study of AR-13324 in Patients With Elevated Intraocular Pressure

CompletedNCT01528787

Aerie PharmaceuticalsOcular Hypertension, Open Angle Glaucoma

Start: 2012-03-31End: 2012-07-31Updated: 2018-04-18

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

CompletedNCT01731002

Aerie PharmaceuticalsOcular Hypertension, Open Angle Glaucoma

Start: 2012-11-30End: 2013-05-31Updated: 2018-04-17

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

CompletedNCT03310580

Aerie PharmaceuticalsPrimary Open Angle Glaucoma or Ocular Hypertension

Start: 2017-11-15End: 2018-10-25Updated: 2019-12-23

Phase 3

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

CompletedNCT02207621

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2014-07-31End: 2016-03-31Updated: 2018-04-06

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02207491

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2014-07-31End: 2015-03-31Updated: 2018-04-13

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02246764

Aerie PharmaceuticalsGlaucoma, Ocular Hypertension

Start: 2014-09-30End: 2016-12-31Updated: 2018-04-06

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

CompletedNCT02558374

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2015-09-30End: 2016-12-31Updated: 2018-04-06